Will EFSA accept that Bifidobacterium BB-12 really improves immune function?

Recently, Rizzardini et al. (B. J. Nutr. 2011) showed that in a vaccination model in healthy subjects supplementation with either Bifidobacterium BB-12 or Lactobacillus casei 431 resulted in significantly greater mean fold increases in total and vaccine-specific antibody titers. However, the question remains whether the observed and statistically significant differences will also be perceived as physiologically relevant by EFSA in […] >> read more